Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Immucell Corp changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 30 | 31 | +1 |
| Shares | 1.06M | 1.06M | +1.22K (+0.1%) |
| Value | $5.42M | $5.32M | −$103.3K (−1.9%) |
New holders (4)
Institutions that held Immucell Corp at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 17,122 | $87.3K | 0.00% |
| Advisor Group Holdings, Inc. | 550 | $2.75K | 0.00% |
| Royal Bank of Canada | 241 | $1.00K | 0.00% |
| Coppell Advisory Solutions LLC | 141 | $698 | 0.00% |
Sold out (3)
Institutions that held Immucell Corp at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Flagship Harbor Advisors, LLC | 14,230 | $72.7K |
| Minerva Advisors LLC | 11,958 | $61.1K |
| FMR LLC | 1 | $5 |